A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
| Condition(s) | Solid Tumor |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors. |
| Who can participate | Inclusion Criteria: 1. Signed, written Independent Ethics Committee (IEC)/Institutional Review Board (IRB)-approved informed consent 2. Age greater than or equal to 18 years 3. Participants consent to provide tumor tissue collected prior to study treatment, preferably from a biopsy performed after their last anticancer therapy and within 90 days of the start of study treatment. An older archival sample may be acceptable with Sponsor approval. 4. Participants must have progressed following, are intolerant of, or have no available standard-of-care therapy. 5. Patients with histologically or cytologically confirmed locally advanced/metastatic relapsed or refractory solid tumors as outlined below: * Dose-escalation and Dose-expansion (Backfill) Cohorts: * Participants with urothelial cancer of |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Biohaven Therapeutics Ltd. |
| Locations | Denver, Colorado, United States; Lake Mary, Florida, United States; Miami, Florida, United States; Detroit, Michigan, United States; Durham, North Carolina, United States; Myrtle Beach, South Carolina, United States (+7 more sites) |
| Start date | 2025-03-20 |
| NCT ID | NCT06874335 |
| Official listing | https://clinicaltrials.gov/study/NCT06874335 |